APLS
Apellis Pharmaceuticals Inc
3.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 99.6% | 99.7% | 99.8% | 99.9% | 99.5% | 95.9% | 95.5% | 93.5% | 94.6% | 97.2% | 89.1% | 94.4% | |
| 95.2% | 94.3% | 90.6% | 96.4% | 86.6% | 90.4% | 58.9% | 72.6% | 72.6% | 44.5% | 46.5% | 43.5% | |
| 95.2% | 94.3% | 90.6% | 96.4% | 86.6% | 90.4% | 91.4% | 79.5% | 72.6% | 44.7% | 47.0% | 43.5% | |
| 3.3% | 4.6% | 4.9% | 0.7% | 0.7% | – | 2.6% | 9.1% | 1.0% | 26.2% | 30.7% | 34.1% | |
| 1.0% | – | – | – | – | – | 0.0% | 2.7% | 11.3% | 18.6% | 9.3% | 13.3% | |
| 0.2% | – | – | – | 0.5% | 4.1% | 2.6% | 3.0% | 3.3% | – | – | – | |
| 7.6% | 8.4% | 13.3% | 18.2% | 20.9% | 91.2% | 78.7% | 77.5% | 77.7% | 75.3% | 74.2% | 65.6% | |
| 7.6% | 8.4% | 13.3% | 3.6% | 8.4% | 16.9% | 13.4% | 15.0% | 22.0% | 31.4% | 21.0% | 30.1% | |
| – | – | – | 14.5% | 0.8% | 0.7% | 0.4% | 0.5% | 0.7% | 0.8% | 0.8% | 9.4% | |
| 5.3% | 6.5% | 9.3% | 2.0% | 5.0% | 2.1% | 0.9% | 1.9% | 4.9% | 4.8% | 4.4% | 5.3% | |
| – | – | – | 14.5% | 12.5% | 36.6% | 37.4% | 21.4% | 12.2% | 11.8% | 51.2% | 33.6% | |
| 92.4% | 91.6% | 86.7% | 81.8% | 79.1% | 8.8% | 21.3% | 22.5% | 22.3% | 24.7% | 25.8% | 34.4% | |
| -172.1% | -186.3% | -358.2% | -82.0% | -136.0% | -149.4% | -96.4% | -187.9% | -303.7% | -359.8% | -343.0% | -280.2% | |
| 126.5% | 47.4% | 66.0% | 7.6% | 26.7% | 16.0% | 7.8% | 9.6% | 14.0% | 15.0% | 14.0% | 11.7% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.